Opus Genetics, Inc. IRD 深 沪
已收盘 08-07 16:00:00 美东时间
3.66
-0.060
-1.61%
华盛通- 最 高3.96
- 今 开3.73
- 成交量 90.56万股
- 最 低 3.525
- 昨 收 3.72
- 总市值 0
- 52周最高 5.81
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.10
- 委 比 -50.13%
- 总股本 --
- 历史最高 13.812
- 量 比 1.11
- 振 幅 11.69%
- 历史最低 0.65
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks That May Rocket Higher In July
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
07-20 18:03
Earnings Summary: Opus Genetics Q4
The earnings results for Opus Genetics (NASDAQ:IRD) for Q4 were made public on ...
03-10 19:26
Where Opus Genetics Stands With Analysts
Providing a diverse range of perspectives from bullish to bearish, 4 analysts h...
03-02 21:00
天津市市场监督管理委员会通报2025年国家与地方联动产品质量监督抽查情况
中国质量新闻网讯 据天津市市场监督管理委员会网站消息，按照《市场监管总局关于印发2025年产品质量国家监督抽查计划的通知》（国市监质监发[2025]24号）要求...
2025-10-21 15:46
Arm发布全新C1 CPU与G1-Ultra GPU：Armv9.3指令集、新一代光追
Arm UNLOCKED 峰会在上海召开。 Arm在此次峰会上正式发布了面向移动端的 Arm Lumex计算子系统(Compute Subsyst...
2025-09-11 10:47
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
Opus Genetics, Inc. received $2 million to advance its OPGx-MERTK gene therapy targeting MERTK-related retinitis pigmentosa, supported by the Retinal Degeneration Fund. The funding aims to accelerate IND-enabling studies, strengthening Opus' pipeline for inherited retinal diseases.
2025-06-23 12:00
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Opus Genetics announced positive Phase 3 results for Phentolamine Ophthalmic Solution 0.75% in treating night vision impairment after keratorefractive surgery. The study met its primary endpoint, showing significant visual improvement and functional benefits in low-light conditions, with no new safety concerns identified.
2025-06-02 12:00
